Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02514083
Title A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.